Mismatch repair deficiency and PD-L1 expression on immune cells have been shown to be biomarkers for immunotherapy in TNBCs, and the tumor mutation burden, tumor-infiltrating lymphocytes (TILs), and transcriptional signatures of immune cells have also been suggested to be potential biomarkers7,8. The gene discussed is CD274; the disease is neoplasm.